The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact

The Consideration of At-Home Administration of Omalizumab

by Anna K Lattos, 2021 PharmD Candidate, Kate Hartkopf PharmD, BCACP, James Langley PharmD, MS

"Part of every pharmacist’s job involves selecting the safest medication regimen to fit each patient’s medical needs and achieve compatibility with individual lifestyles. Over time, developments in monoclonal antibody therapies have provided symptom control benefits for patients living with severe allergic asthma. Omalizumab (Xolair®), a monoclonal antibody medication for IgE-mediated asthma, was approved by the FDA for in-clinic use in 2003. In 2018, the European Commission approved this agent’s use for at-home self-administration; this supported increased access and fewer in-clinic trips for patients. However, in the United States, omalizumab largely remains administered in the clinic only."

Keywords: Omalizumab, Anaphylaxis, Antibodies, Monoclonal, Self Administration, Syringes, Drug Labeling, Pharmacists, COVID-19, Asthma, Epinephrine, Histamine Antagonists, Immunoglobulin E, Risk Factors, Biological Products, Ambulatory Care

Download PDF 

2021 January/February Table of Contents 

The Journal of the Pharmacy Society of Wisconsin


Past Issues

2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

thejournal@pswi.org
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Editorial Plans
    • Submit a Manuscript
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • About
    • Advertise in The Journal
    • Editorial Advisory Committee
  • Contact